Hims & Hers Health, Inc. (HIMS) Stock Analysis and Metrics

Hims & Hers Health

NYSE: HIMS

$28.08 ▼ -4.66 (-14.22%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap6.44 Bn

P/E-486.57

P/S2.72

Div. Yield0.00

ROIC (Qtr)-0.03

Revenue Growth (1y) (Qtr)3.77

Add ratio to table…

About

Hims & Hers Health, Inc. is a consumer first health and wellness platform launched in 2017. The company provides telehealth consultations that connect patients with licensed healthcare professionals who can prescribe medications when appropriate. It also offers a range of non prescription health and wellness products and laboratory testing services through its digital platform. The platform includes an electronic medical record system digital prescription capabilities cloud pharmacy fulfillment and personalization tools. Hims & Hers Health, Inc. serves customers in the United States Canada the United Kingdom and several European Union countries including Germany Ireland France and Spain.

The company generates revenue primarily through subscription based sales of prescription medications over the counter products and laboratory testing services. Prescription offerings include generic brand name and compounded medications that are fulfilled through its own pharmacies or partner pharmacies. Over the counter items consist of drug and device products cosmetics and supplements that are sold directly to consumers and through retail partnerships. Laboratory testing services provide biomarker measurements that support health assessment and ongoing clinical management. Many of these offerings are sold on recurring subscription plans which create predictable revenue streams and encourage long term customer engagement.

Hims & Hers Health, Inc. occupies a distinctive place in the digital health and telehealth industry by combining a trusted consumer brand with vertically integrated capabilities such as owned pharmacies a peptide manufacturing facility and a laboratory testing site. While it faces competition from traditional healthcare providers large retailers and niche telehealth firms the company differentiates itself through its technology driven platform clinical excellence and ability to offer personalized treatment plans across multiple therapeutic areas. Its integrated model allows it to control parts of the supply chain reduce reliance on third party pharmacy relationships and accelerate speed to market for new products.

The company’s customer base consists mainly of individual consumers seeking convenient and affordable care for conditions such as sexual health hair loss weight loss hormone health dermatology and mental health. It also serves patients who access laboratory testing for wellness monitoring and those who benefit from partnerships with established health systems. Specific partner organizations include Ochsner Health Mount Sinai Health System Carbon Health ChristianaCare Health System and Hartford Healthcare. In the United Kingdom Hims & Hers Health, Inc. works with platform partners such as Asda Stores Limited and Superdrug Stores PLC to extend its reach. These relationships combined with a direct to consumer approach enable the company to serve a diverse demographic across multiple geographic markets.

Investment Thesis

▲ Bull case

The company’s strategic shift to branded GLP 1 products is unlocking a material expansion of its addressable market and driving robust subscriber growth. In the weeks following the launch of Wegovy on the platform the firm added more than 100,000 new subscribers per month to its weight loss vertical and early engagement metrics show nearly 90% of these users downloading the app and interacting with a provider three times in the first month. This influx not only raises top line revenue but also creates a powerful cross sell engine for other specialties such as testosterone menopause and labs. The management views this as a foundational step toward becoming the default health and wellness provider in the United States and eventually globally.
Global scale is becoming a durable competitive advantage through the pending acquisition of Eucalyptus and the existing footprint from ZAVA and LIVWELL. Once closed the Eucalyptus deal will extend the platform’s leadership into Australia the United Kingdom Germany Japan and Canada adding hundreds of millions of potential users to the ecosystem. This international breadth amplifies network effects because each new geography contributes unique data points that improve the AI driven personalization engine and makes the platform more attractive to pharma and biotech partners seeking distribution. The company believes its high touch personalized experience will help customers adhere to therapy longer than medication alone thereby increasing lifetime value and strengthening the moat around its service model.
Investments in data and technology are constructing a closed loop data flywheel that is increasingly difficult for rivals to replicate. The platform now captures consumer intake diagnosis treatment journey provider decisions and outcomes in a single stack allowing every interaction to train models with clinician verified labels. Recent AI releases such as Labs AI and the upcoming weight loss companion demonstrate how the firm is embedding intelligence at every step of the care journey while maintaining guardrails that keep providers in control of clinical decisions. As the data set grows the models become smarter leading to faster more accurate recommendations higher engagement and better health outcomes which in turn fuels further data creation a virtuous cycle that supports long term margin expansion and defensibility.
The balance sheet reflects significant financial flexibility that can be deployed to accelerate growth without excessive dilution. At the end of Q1 FY26 the company held roughly 751,000,000 in cash and short term investments and generated 89,000,000 of operating cash flow and 53,000,000 of free cash flow. The recent 350,000,000 zero coupon convertible note offering paired with capped call transactions limits potential dilution while providing capital for the Eucalyptus acquisition technology upgrades and AI scaling. Management expects operating leverage to emerge in the second half of the year as G&A expenses benefit from scale marketing efficiency improves and monthly cohorts from the weight loss push begin to compound resulting in accelerating adjusted EBITDA growth toward the long term target of at least 1,300,000,000 by 2030.

The company’s strategic shift to branded GLP 1 products is unlocking a material expansion of its addressable market and driving robust subscriber growth. In the weeks following the launch of Wegovy on the platform the firm added more than 100,000 new subscribers per month to its weight loss vertical and early engagement metrics show nearly 90% of these users downloading the app and interacting with a provider three times in the first month. This influx not only raises top line revenue but also creates a powerful cross sell engine for other specialties such as testosterone menopause and labs. The management views this as a foundational step toward becoming the default health and wellness provider in the United States and eventually globally.
Global scale is becoming a durable competitive advantage through the pending acquisition of Eucalyptus and the existing footprint from ZAVA and LIVWELL. Once closed the Eucalyptus deal will extend the platform’s leadership into Australia the United Kingdom Germany Japan and Canada adding hundreds of millions of potential users to the ecosystem. This international breadth amplifies network effects because each new geography contributes unique data points that improve the AI driven personalization engine and makes the platform more attractive to pharma and biotech partners seeking distribution. The company believes its high touch personalized experience will help customers adhere to therapy longer than medication alone thereby increasing lifetime value and strengthening the moat around its service model.
Investments in data and technology are constructing a closed loop data flywheel that is increasingly difficult for rivals to replicate. The platform now captures consumer intake diagnosis treatment journey provider decisions and outcomes in a single stack allowing every interaction to train models with clinician verified labels. Recent AI releases such as Labs AI and the upcoming weight loss companion demonstrate how the firm is embedding intelligence at every step of the care journey while maintaining guardrails that keep providers in control of clinical decisions. As the data set grows the models become smarter leading to faster more accurate recommendations higher engagement and better health outcomes which in turn fuels further data creation a virtuous cycle that supports long term margin expansion and defensibility.
The balance sheet reflects significant financial flexibility that can be deployed to accelerate growth without excessive dilution. At the end of Q1 FY26 the company held roughly 751,000,000 in cash and short term investments and generated 89,000,000 of operating cash flow and 53,000,000 of free cash flow. The recent 350,000,000 zero coupon convertible note offering paired with capped call transactions limits potential dilution while providing capital for the Eucalyptus acquisition technology upgrades and AI scaling. Management expects operating leverage to emerge in the second half of the year as G&A expenses benefit from scale marketing efficiency improves and monthly cohorts from the weight loss push begin to compound resulting in accelerating adjusted EBITDA growth toward the long term target of at least 1,300,000,000 by 2030.

▼ Bear case

Near term profitability is under pressure because the shift to branded GLP 1 products has introduced substantial one time costs and gross margin compression. The firm recorded approximately 33,000,000 of restructuring charges related to the write down of its compounded GLP 1 supply chain which reduced GAAP gross margin to 65% and adjusted gross margin to 70% in Q1 FY26. These costs along with legal and merger related expenses drove a GAAP net loss of 92,000,000 and lowered adjusted EBITDA margin to 7% for the quarter. While management anticipates improvement the current margin profile shows that the transition is weighing heavily on earnings and could persist if pricing dynamics with branded partners evolve unfavorably.
Revenue recognition volatility stemming from the move to shorter shipping cadences creates uncertainty in quarterly top line trends and may obscure underlying performance. The company noted that U S revenue was temporarily pressured by the shift from a two month to a one month shipment cycle for weight loss products which altered the timing of revenue recognition and made year over year comparisons difficult. This accounting shift can cause fluctuations that are not reflective of real demand and may lead to mispricing of the stock by investors who rely on headline revenue figures without adjusting for the cadence change. Consequently analysts may need to adjust their models to account for the shifted cadence when forecasting future quarters.
The peptide opportunity while promising remains uncertain and could require significant investment before generating meaningful returns. Management acknowledged that they will not launch peptide therapies until they meet high standards for physician oversight supply chain safety and clinical validation which implies additional spending on facilities talent and regulatory work. The regulatory path for peptides is still evolving and the FDA has not yet provided clear guidance on which molecules will be allowed for mass market use. If the company misjudges the timing or scale of demand it could incur sunk costs that dilute returns and distract from core growth initiatives.
International expansion carries execution risk that could erode the anticipated benefits of the Eucalyptus acquisition and other overseas assets. Integrating businesses across disparate regulatory environments cultures and healthcare systems is complex and the firm has limited experience scaling its model outside of the United States at the scale implied by the deal. Any delays in closing the Eucalyptus transaction difficulties in harmonizing provider networks or unexpected costs associated with localization could postpone the realization of synergies and increase the cash burn associated with the overseas push. Moreover competition in markets such as Canada the United Kingdom and Australia is intensifying as local players and global entrants ramp up their own digital health offerings which may limit the company’s ability to capture the projected TAM.

Near term profitability is under pressure because the shift to branded GLP 1 products has introduced substantial one time costs and gross margin compression. The firm recorded approximately 33,000,000 of restructuring charges related to the write down of its compounded GLP 1 supply chain which reduced GAAP gross margin to 65% and adjusted gross margin to 70% in Q1 FY26. These costs along with legal and merger related expenses drove a GAAP net loss of 92,000,000 and lowered adjusted EBITDA margin to 7% for the quarter. While management anticipates improvement the current margin profile shows that the transition is weighing heavily on earnings and could persist if pricing dynamics with branded partners evolve unfavorably.
Revenue recognition volatility stemming from the move to shorter shipping cadences creates uncertainty in quarterly top line trends and may obscure underlying performance. The company noted that U S revenue was temporarily pressured by the shift from a two month to a one month shipment cycle for weight loss products which altered the timing of revenue recognition and made year over year comparisons difficult. This accounting shift can cause fluctuations that are not reflective of real demand and may lead to mispricing of the stock by investors who rely on headline revenue figures without adjusting for the cadence change. Consequently analysts may need to adjust their models to account for the shifted cadence when forecasting future quarters.
The peptide opportunity while promising remains uncertain and could require significant investment before generating meaningful returns. Management acknowledged that they will not launch peptide therapies until they meet high standards for physician oversight supply chain safety and clinical validation which implies additional spending on facilities talent and regulatory work. The regulatory path for peptides is still evolving and the FDA has not yet provided clear guidance on which molecules will be allowed for mass market use. If the company misjudges the timing or scale of demand it could incur sunk costs that dilute returns and distract from core growth initiatives.
International expansion carries execution risk that could erode the anticipated benefits of the Eucalyptus acquisition and other overseas assets. Integrating businesses across disparate regulatory environments cultures and healthcare systems is complex and the firm has limited experience scaling its model outside of the United States at the scale implied by the deal. Any delays in closing the Eucalyptus transaction difficulties in harmonizing provider networks or unexpected costs associated with localization could postpone the realization of synergies and increase the cash burn associated with the overseas push. Moreover competition in markets such as Canada the United Kingdom and Australia is intensifying as local players and global entrants ramp up their own digital health offerings which may limit the company’s ability to capture the projected TAM.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password